2Q Revenues: $5.2 billion (+16%)
2Q Earnings: $764.0 million (+8%)
YTD Revenues: $10.1 billion (+19%)
YTD Earnings: $1.4 billion (+2%)
Comments: Pharmaceutical sales in the quarter were $4.5 billion (+16%). U.S. pharma sales were $2.6 billion (+17%) due to increased sales of Plavix, Abilify growth, and the HIV and hepatitis portfolio, as well as contributions from recent product launches, Orencia and Ixempra. Plavix sales were $1.4 billion (+17%) in the quarter. Abilify sales were up 28% to $529 million. Reyataz sales were $324 million (+28%). Sustiva Franchise revenues were $282 million (+21%). Baraclude sales were $136 million (+131%). Orencia sales were $106 million (+93%). Ixempra sales were $26 million in the quarter. R&D expenses were up 9% to $826 million in the quarter. Acquired in-process R&D charges were $32 million, related to the acquisition of Kosan Biosciences, Inc.